NEWSROOM

In the clinical study conducted by ENBIOSIS, a Turkish biotechnology startup that develops personal nutrition programs by analyzing bacteria in the human intestine with microbiome tests, 78% of the patients with irritable bowel syndrome have observed improvement in symptoms.

*** This release is originally published in Turkish.
Google Translate Application translates the content you see on this page.***

ISTANBUL (TR) - Research on the relationship of bacteria in the gut, called microbiome elements, with human health continues to gain momentum all over the world. ENBIOSIS, a Turkish biotechnology initiative aiming to develop personalized health solutions for the treatment of many health problems such as obesity, diabetes and eczema, through bacteria in the human intestine by taking part in the researches carried out in this field, has achieved a significant success with its clinical study on IBS, which is popularly known as Irritable Bowel Syndrome. In the statement made by ENBIOSIS, it was reported that 78% of IBS patients who were applied personalized diets improved their symptoms. This result was considered to be an important scientific outcome that microbiome-based diet application could show promise for IBS treatment.

Ethics committee approval was obtained from Gazi University

Speaking about the details of the clinical study, ENBIOSIS CTO Özkan Ufuk Nalbantoğlu said, “At the first stage of our study, which we conducted with the approval of the ethics committee from Gazi University, stool samples were collected from patients who met the criteria for participation in the study diagnosed with Irritable Bowel Syndrome, and then the patients were divided into two groups. and the first group was followed by dieticians for 6 weeks with the microbiome-based personalized diet developed by ENBIOSIS. The second group, that is the control group, was followed up with a standard nutrition program for 6 weeks. These needs were created on an individual basis and in an alternative way based on the microbiome, not according to the elimination diets. progressed over. At the end of six weeks, stool samples were again collected from both groups and microbiome analyzes were performed in comparison with the first samples.”

The study will be presented at an international congress

Ufuk Nalbantoğlu made the following statements regarding the results of the study: “Concurrently with the results of the study, the clinical conditions of the patients were followed for 6 weeks by the Gastroenterology specialists involved in the study and scored before the diet (IBS-SSS). At the end of the study, we observed statistically significant improvements in the ENBIOSIS diet group compared to the standard diet group on the basis of both microbiome profile and clinical findings. Gastroenterology experts reported that 78% of the ENBIOSIS diet group had severe symptoms at the beginning of the study, while all patients had severe symptoms. Similarly, significant changes were found in the microbiome profile of the patients in the ENBISOS diet group in certain bacterial groups characterized by IBS compared to the other group. We want to announce these results in the scientific field as soon as possible. We started article writing as a team, we have a plan to present our results at an international congress before publication.”

The power of personalized healthcare solutions is proven

Emphasizing that they aim to spread disease prevention and treatment support approaches through the intestinal microbiome, Nalbantoğlu said, “Increasing number of scientific studies in recent years indicate that the bacterial balance in the intestines is related to many diseases. As ENBIOSIS, we aim to support the treatment processes of diseases such as Crohn's, ulcerative colitis, irritable bowel syndrome, obesity and eczema with personalized diets, based on literature data and current studies. In this direction, we analyze the bacteria in the intestine at the first stage and map the current situation and then determine the nutrients needed on an individual basis to reach the healthy one or to achieve bacterial balance. With our clinical study on IBS, we think that we have made an important development for the literature. This study is particularly proud as it proves the power of personalized health solutions based on microbiome. The achievements of ENBIOSIS are closely followed in the global arena. Lastly, we were chosen as the 1st among 114 global start-ups in the “When Healthtech Meets Insurance” event organized by NN Sigorta.”